<div><div></div><div>Shattuck Labs entered into a Sales Agreement with Leerink Partners to offer and sell up to $75 million of common stock through an at-the-market program. Sales, if any, may be made at market prices, and the company may suspend or terminate the program at any time. The agent will receive up to a 3.0% commission on gross proceeds. Shattuck plans to use any proceeds to advance clinical trials, develop additional candidates, and for working capital and general purposes.Agreement details:<ul><li>Agreement type: At-the-market equity offering sales agreement for up to $75 million</li><li>Counterparty: Leerink Partners</li><li>Signed / Effective: Jan 22 2026 / same</li><li>Duration / Termination: At will</li><li>Reason: Fund clinical trials and general corporate purposes</li></ul>Original SEC Filing: Shattuck Labs, Inc. [ STTK ] - 8-K - Jan. 22, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

IBBQ

STTK

SBIO

Shattuck Labs has signed an at-the-market sales agreement with Leerink Partners to sell up to $75 million of common stock. The sales will occur at market prices, and the company can suspend or terminate the program at any time. The agent will earn a commission of up to 3.0% on gross proceeds. Proceeds will be used for advancing clinical trials, developing additional candidates, and general corporate purposes. The agreement is effective from January 22, 2026, and can be terminated at will.

Shattuck Labs Signs At-The-Market Sales Agreement With Leerink Partners